Biltmore Family Office LLC decreased its position in Pfizer Inc. (NYSE:PFE) by 60.3% during the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 33,360 shares of the biopharmaceutical company’s stock after selling 50,620 shares during the period. Biltmore Family Office LLC’s holdings in Pfizer were worth $1,210,000 as of its most recent SEC filing.

Other institutional investors have also recently modified their holdings of the company. HC Financial Advisors Inc. purchased a new position in Pfizer in the fourth quarter valued at about $2,685,000. Bridges Investment Management Inc. raised its position in Pfizer by 12.5% in the fourth quarter. Bridges Investment Management Inc. now owns 119,960 shares of the biopharmaceutical company’s stock valued at $4,345,000 after purchasing an additional 13,308 shares during the period. Schroder Investment Management Group raised its position in Pfizer by 3.5% in the fourth quarter. Schroder Investment Management Group now owns 13,501,677 shares of the biopharmaceutical company’s stock valued at $489,030,000 after purchasing an additional 456,811 shares during the period. BlackRock Inc. grew its stake in shares of Pfizer by 2.8% during the fourth quarter. BlackRock Inc. now owns 452,745,609 shares of the biopharmaceutical company’s stock valued at $16,398,445,000 after acquiring an additional 12,183,218 shares in the last quarter. Finally, UBS Asset Management Americas Inc. grew its stake in shares of Pfizer by 0.8% during the fourth quarter. UBS Asset Management Americas Inc. now owns 19,905,893 shares of the biopharmaceutical company’s stock valued at $720,991,000 after acquiring an additional 155,942 shares in the last quarter. Hedge funds and other institutional investors own 69.12% of the company’s stock.

NYSE:PFE opened at $42.20 on Friday. The stock has a market capitalization of $249.13 billion, a P/E ratio of 15.92, a PEG ratio of 2.01 and a beta of 0.96. Pfizer Inc. has a one year low of $33.20 and a one year high of $42.77. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.16 and a quick ratio of 0.91.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, July 31st. The biopharmaceutical company reported $0.81 EPS for the quarter, topping the Zacks’ consensus estimate of $0.74 by $0.07. The business had revenue of $13.47 billion during the quarter, compared to the consensus estimate of $13.30 billion. Pfizer had a return on equity of 25.35% and a net margin of 42.35%. The company’s revenue for the quarter was up 4.4% compared to the same quarter last year. During the same period last year, the firm earned $0.67 earnings per share. analysts predict that Pfizer Inc. will post 2.99 EPS for the current year.

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 4th. Investors of record on Friday, August 3rd were paid a $0.34 dividend. The ex-dividend date was Thursday, August 2nd. This represents a $1.36 dividend on an annualized basis and a yield of 3.22%. Pfizer’s dividend payout ratio (DPR) is 51.32%.

In other Pfizer news, VP Loretta V. Cangialosi sold 26,814 shares of the firm’s stock in a transaction dated Wednesday, August 1st. The shares were sold at an average price of $40.16, for a total value of $1,076,850.24. Following the transaction, the vice president now owns 102,360 shares of the company’s stock, valued at $4,110,777.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Laurie J. Olson sold 10,214 shares of the firm’s stock in a transaction dated Monday, August 13th. The stock was sold at an average price of $41.00, for a total transaction of $418,774.00. Following the completion of the transaction, the insider now directly owns 72,672 shares in the company, valued at approximately $2,979,552. The disclosure for this sale can be found here. Insiders sold 761,230 shares of company stock valued at $29,054,690 over the last quarter. Insiders own 0.06% of the company’s stock.

Several brokerages have recently weighed in on PFE. Zacks Investment Research downgraded Pfizer from a “buy” rating to a “hold” rating in a research note on Sunday, July 15th. BMO Capital Markets raised their target price on Pfizer to $47.00 and gave the company an “outperform” rating in a research note on Friday. Cantor Fitzgerald set a $45.00 target price on Pfizer and gave the company a “buy” rating in a research note on Wednesday, June 13th. JPMorgan Chase & Co. restated a “buy” rating and set a $42.00 target price on shares of Pfizer in a research note on Thursday, August 23rd. Finally, Morningstar set a $46.00 target price on Pfizer and gave the company a “buy” rating in a research note on Tuesday, August 28th. Two equities research analysts have rated the stock with a sell rating, twelve have given a hold rating and nine have issued a buy rating to the stock. Pfizer presently has a consensus rating of “Hold” and a consensus target price of $41.89.

About Pfizer

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.

Read More: Fundamental Analysis and Individual Investors

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.